Sovateltide for Acute Ischemic Stroke
Sovateltide (0.3 µg/kg IV) should be administered in three doses at 3±1 hour intervals on Days 1,3, and 6 to adult patients (18-78 years) with acute cerebral ischemic stroke presenting within 24 hours of symptom onset who have an NIHSS ≥6 and radiologically confirmed ischemic stroke. This recommendation is based on the Phase III trial that led to regulatory approval in India 1.
Dosing and Administration
Dose: 0.3 µg/kg administered as an intravenous bolus over 1 minute 1, 2
Schedule:
- Day 1: Three doses at 3±1 hour intervals
- Day 3: Three doses at 3±1 hour intervals
- Day 6: Three doses at 3±1 hour intervals
- Total daily dose: 0.9 µg/kg per treatment day
The drug was administered at a median of 18 hours after stroke onset in the pivotal trial 1. Earlier administration within the 24-hour window is preferable, with 70-78% of patients in clinical trials receiving treatment within 20-24 hours 2.
Patient Eligibility Criteria
Include patients with:
- Age 18-78 years 1
- Acute cerebral ischemic stroke with radiologic confirmation
- Presentation within 24 hours of symptom onset (or last known well)
- NIHSS score ≥6 at randomization 1
- Standard of care for stroke already initiated
Exclude patients with:
- Recurrent stroke 1
- Intracranial hemorrhage 1, 2
- Patients receiving endovascular therapy 1, 2
- Full-term or premature infants less than 1 month old 3
- Children less than 12 years old (may lead to irritation) 3
Compatibility with Standard Stroke Treatments
Sovateltide can be administered alongside standard acute stroke care, including IV thrombolysis with alteplase or tenecteplase. The Phase III trial enrolled patients receiving standard of care, and sovateltide was given as an adjunctive therapy 1. However, patients who received endovascular thrombectomy were specifically excluded from the trials 1, 2.
The timing allows for sequential administration: if a patient receives IV alteplase (which must be given within 3-4.5 hours per guidelines 4, 5), sovateltide can still be initiated within the 24-hour window on the same day, then continued on Days 3 and 6.
Monitoring Requirements
Hemodynamic monitoring: Blood pressure, heart rate, and basic vital signs should be monitored, though the Phase III trial showed no significant effects on hemodynamic parameters 2.
Laboratory monitoring:
- Biochemical and hematological parameters were unaffected in clinical trials 2
- No specific laboratory monitoring beyond standard stroke care is required
Neurological assessment:
- NIHSS scores should be tracked from baseline through Day 90
- Modified Rankin Scale (mRS) assessments at Days 6,30,60, and 90
- Barthel Index at similar intervals 1, 2
Imaging surveillance: Monitor for intracranial hemorrhage, particularly within the first 36 hours, as 8.75% of sovateltide-treated patients developed ICH in the Phase III trial (similar to the 8.97% rate in controls) 1.
Safety Profile and Adverse Events
Sovateltide demonstrated excellent tolerability with no drug-related adverse events in the Phase II trial 2 and adverse events comparable to placebo in Phase III 1.
Intracranial hemorrhage rates: 8.75% in the sovateltide group versus 8.97% in controls—these events were not attributed to sovateltide 1. This rate is consistent with the natural history of acute ischemic stroke and standard care.
No hemodynamic instability: Despite being an endothelin-B receptor agonist, sovateltide did not cause clinically significant changes in blood pressure or other hemodynamic parameters 2.
Expected Outcomes
At 90 days post-treatment, sovateltide-treated patients showed:
- 22.67% higher proportion achieving mRS 0-2 (functional independence) compared to controls (OR 2.75,95% CI 1.37-5.57) 1
- 17.05% more patients achieving NIHSS 0-5 (OR 2.67,95% CI 1.27-5.90) 1
- 51.28% of controls versus 72.50% of sovateltide patients showed ≥2-point improvement on mRS (OR 2.50,95% CI 1.29-4.81) 1
Critical Caveats
Regulatory status: Sovateltide is currently approved only in India 6. A multinational RESPECT-ETB trial is planned for US FDA approval 1. Use outside India would be off-label or investigational.
Endovascular therapy exclusion: The evidence base specifically excluded patients receiving mechanical thrombectomy 1, 2. If endovascular therapy is planned or performed, sovateltide's safety and efficacy in this context is unknown.
Mechanism of action: Sovateltide works through endothelin-B receptor agonism to increase cerebral blood flow, provide anti-apoptotic effects, and promote neurovascular remodeling 1, 2. This mechanism is distinct from thrombolysis and addresses neural repair rather than clot dissolution.
Time window rationale: The 24-hour window is broader than traditional thrombolytic therapy (3-4.5 hours for alteplase 4, 5) because sovateltide's neuroprotective and neurorestorative mechanisms operate through different pathways than acute reperfusion.